Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | RPLP1 | P05386 | 2/20 | 0.33 |
| ▸ | RPLP0 | P05388 | 2/20 | 0.33 |
| ▸ | RPS17 | P08708 | 2/20 | 0.33 |
| ▸ | RPSA | P08865 | 2/20 | 0.33 |
| ▸ | RPS2 | P15880 | 2/20 | 0.33 |
| ▸ | RPL35A | P18077 | 2/20 | 0.33 |
| ▸ | RPL7 | P18124 | 2/20 | 0.33 |
| ▸ | RPL17 | P18621 | 2/20 | 0.33 |
| ▸ | RPS4Y1 | P22090 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085739 | 0.92 | TRPV1 (0.43) | CXCR4TRPV1TDP1CCR5KCNH2 | |
| SCHEMBL2084022 | 0.91 | CXCR4 (0.38) | CXCR4TRPV1TDP1CCR5KCNH2 | |
| SCHEMBL12935380 | 0.90 | CXCR4 (0.37) | CXCR4TRPV1CCR5KCNH2HSD11B1 | |
| SCHEMBL2086368 | 0.88 | CXCR4 (0.36) | CXCR4TRPV1TDP1 | |
| SCHEMBL2083524 | 0.87 | OPRL1 (0.36) | CXCR4CCR5KCNH2GSK3BDYRK1A | |
| SCHEMBL2081761 | 0.87 | TRPV1 (0.36) | CXCR4TRPV1CCR5KCNH2HSD11B1 | |
| SCHEMBL2084834 | 0.85 | TRPV1 (0.38) | CXCR4TRPV1SMOCYP3A4 | |
| SCHEMBL2083283 | 0.83 | CXCR4 (0.39) | CXCR4TRPV1TDP1GSK3BDYRK1A | |
| SCHEMBL2084270 | 0.82 | CXCR4 (0.40) | CXCR4TDP1CCR5KCNH2HSD11B1 | |
| SCHEMBL2084919 | 0.82 | TDP1 (0.42) | CXCR4TRPV1TDP1CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | claimed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | claimed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | claimed |
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1613613-A4 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1613613-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091518-A2 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | CXCR4 1/4885TRPV1 1269/4885TDP1 2809/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | CXCR4 1/4885TRPV1 625/4885TDP1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.